NASDAQ:SLS SELLAS Life Sciences Group Q2 2026 Earnings Results & Report $12.30 -0.11 (-0.92%) As of 09:58 AM Eastern This is a fair market value price provided by Massive. Learn more. SELLAS Life Sciences Group missed analyst earnings expectations in its Q2 2026 results, released August 11, 2026. The company reported EPS of -$0.05 versus the -$0.0450 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 11, 2026TimeAfter Market ClosesConference Call7:00 AM ET SELLAS Life Sciences Group EPS ResultsActual EPS-$0.05Consensus EPS -$0.0450Beat/MissMissed by -$0.0050One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersSELLAS Life Sciences Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSELLAS Life Sciences Group's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) SELLAS Life Sciences Group Q2 2026 Earnings FAQ Did SELLAS Life Sciences Group beat earnings estimates for Q2 2026? SELLAS Life Sciences Group (NASDAQ:SLS) reported earnings of -$0.05 per share for Q2 2026, missing the consensus estimate of -$0.0450. The report was announced on Tuesday, August 11, 2026. When is SELLAS Life Sciences Group's next earnings date? SELLAS Life Sciences Group's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for SELLAS Life Sciences Group on the company's earnings history page. SELLAS Life Sciences Group Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSOctober 6, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSOctober 1, 2026 | prnewswire.comMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3September 30, 2026 | insidermonkey.comCan SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?September 30, 2026 | finance.yahoo.comSELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer DataSeptember 30, 2026 | finance.yahoo.comSee More SELLAS Life Sciences Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email. Email Address About SELLAS Life Sciences GroupSELLAS Life Sciences Group (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company’s research and development programs are designed to address cancers with significant unmet medical needs. SELLAS’s lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms’ tumor 1 (WT1), a protein expressed in several types of cancer. The company has been evaluating GPS primarily in acute myeloid leukemia, including in the Phase 3 REGAL clinical trial for patients with relapsed or refractory disease. The company is also developing SLS009, a selective cyclin-dependent kinase 9 (CDK9) inhibitor being studied in oncology indications, including acute myeloid leukemia and certain solid tumors. SELLAS conducts clinical development activities through collaborations and research programs intended to support the advancement of its pipeline in the United States and other markets. The company was formerly known as Galena Biopharma, Inc. and is led by President and Chief Executive Officer Angelos Stergiou, M.D., Sc.D.View SELLAS Life Sciences Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
